Advertisement
Advertisement
VYNE
VYNE Therapeutics Inc. Common Stock
0.66
USDSponsored
-0.01
-1.92%
May 08, 14:40 UTC -4
Closed
After-Market
0.65
-0.01
-1.30%
VYNE Earnings Reports
Positive Surprise Ratio
VYNE beat 21 of 33 last estimates.
64%
Next Report
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$204.00K
/-$0.18
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
+195.65%
/+38.46%
VYNE Therapeutics Inc. Common Stock earnings per share and revenue
On May 06, 2026, VYNE reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -0.18 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 204.00 thousand, with a --% difference.
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.18 USD, with revenue projected to reach 204.00 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Quoin Pharmaceuticals, Ltd. - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.96
Actual
-$1.77
Surprise
+9.93%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
FAQ
What were VYNE Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, VYNE Therapeutics Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to VYNE Therapeutics Inc. Common Stock's Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is VYNE Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for VYNE Therapeutics Inc. Common Stock's next earnings report?
Based on 3
analysts, VYNE Therapeutics Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $204.00K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement